Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, MSC 635 CSB 903, Charleston, SC 29425, USA.
Curr Hematol Malig Rep. 2013 Jun;8(2):156-62. doi: 10.1007/s11899-013-0158-1.
Therapies for AML have remained mostly unchanged since the introduction of anthracyline- and cytarabine-based regimens in the 1970s. Though some changes have been made in the dosing of anthracylines, in the choice of consolidation regimens versus allogeneic stem cell transplant, and in supportive care, clinical outcomes remain poor for most patients. As we continue to strive for better treatment options to improve upon outcomes, different agents, both chemotherapeutic and targeted therapies, are being studied. Here we discuss new chemotherapeutic agents that show promise in recent clinical trials and attempt to answer the question if there are any new effective cytotoxic chemotherapy agents out there.
自 20 世纪 70 年代蒽环类药物和阿糖胞苷为基础的方案问世以来，AML 的治疗方法基本没有改变。尽管在蒽环类药物的剂量、巩固治疗方案与异基因造血干细胞移植的选择以及支持性治疗方面进行了一些调整，但大多数患者的临床结局仍然较差。随着我们继续努力寻找更好的治疗选择以改善预后，不同的药物，包括化疗药物和靶向治疗药物，正在被研究。在这里，我们讨论了在最近的临床试验中显示出前景的新型化疗药物，并试图回答是否有新的有效的细胞毒化疗药物这一问题。
